Golidocitinib Plus Anthracycline-based Therapy for Untreated Nodal T-follicular Helper (TFH) Cell Lymphoma
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorSun Yat-sen University
About this trial
This is a prospective, multicenter, open-label, single-arm, phase II clinical study to evaluate the safety and efficacy of golidocitinib in combination with an anthracycline-based regimen as first-line treatment for patients with previously untreated nodal T-follicular helper (TFH) cell lymphoma.
Eligibility criteria
Qualifiers
Histologically confirmed nodal T-follicular helper (TFH) cell lymphoma according to the 2022 WHO classification.
Previously untreated with systemic anti-lymphoma therapy.
Age ≥18 and <75 years.
At least one measurable or evaluable lesion according to the Lugano 2014 criteria.
Disqualifiers
Hemophagocytic syndrome.
Central nervous system or meningeal involvement by lymphoma.
Patients with a history of other malignancies within the past 5 years or concurrent malignancies, except for basal cell carcinoma of the skin.
Patients receiving potent CYP3A inducers or inhibitors, vitamin K antagonists, antiplatelet agents, or anticoagulants.
Trial design
Treatments tested in this trial
- Golidocitinib
- Doxorubicin
- Epirubicin
Treatment groups
47 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov